Cabio Biotech (Wuhan) Co., Ltd. (688089.SS)
CNY 20.17
(-0.93%)
CNY 20.17
(-0.93%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 68.88 Million | 176.4 Million | 103.29 Million | 145.88 Million | 131.94 Million | 106.16 Million |
| Net Income | 86.36 Million | 61.58 Million | 131.29 Million | 134.93 Million | 119.75 Million | 97.82 Million |
| Depreciation & Amortization | 48.34 Million | 27 Million | 23.96 Million | 26.01 Million | 28.97 Million | 27.83 Million |
| Deferred income taxes | 132.49 Thousand | -5.23 Million | -163.16 Thousand | -151.92 Thousand | -77.24 Thousand | -751 Thousand |
| Stock-based compensation | -4.35 Million | 13.4 Million | - | - | - | - |
| Change in working capital | -77.67 Million | 24.18 Million | -43.76 Million | -3.59 Million | -21 Million | -28.79 Million |
| Other non-cash items | 860.91 Thousand | 55.45 Million | -8.19 Million | -11.47 Million | 4.22 Million | 9.29 Million |
| Investing Cash Flow | -287.29 Million | -338.53 Million | -250.37 Million | -80.47 Million | -13.28 Million | -25.81 Million |
| Investments in PPE | -297.67 Million | -249.46 Million | -173.42 Million | -33.09 Million | -23.27 Million | -12.34 Million |
| Acquisitions | 16.8 Million | 159.77 Thousand | 1.66 Million | 174.94 Thousand | 8.67 Million | - |
| Investment purchases | -30.14 Million | -75.11 Million | -88.85 Million | -56.77 Million | -204 Million | -13.72 Million |
| Sales/Maturities of investments | 7.49 Million | 8.68 Million | 11.72 Million | 19.22 Million | 1.31 Million | 211.71 Thousand |
| Other Investing Activities | 32.77 Million | -22.79 Million | -1.46 Million | -9.99 Million | 204 Million | 44.57 Thousand |
| Financing Cash Flow | -34.01 Million | -10.83 Million | -39.36 Million | -63.94 Million | 602.84 Million | -36.1 Million |
| Debt repayment | -19 Million | -30 Million | -30 Million | - | -1 Million | - |
| Dividends payments | -36.06 Million | -39.6 Million | -39.6 Million | -60 Million | -45 Million | -36 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 21.56 Million | 59.01 Million | 30.5 Million | -3.94 Million | 648.84 Million | -104.35 Thousand |
| Accounts receivables | -45.73 Million | -61.47 Million | -47.71 Million | -9.68 Million | -10.91 Million | -55.78 Million |
| Accounts payables | 7.51 Million | 100.11 Million | 8.98 Million | 3.66 Million | -11.68 Million | 13.01 Million |
| Inventory | -39.58 Million | -9.22 Million | -4.87 Million | 2.57 Million | 1.67 Million | 14.71 Million |
| Other working capital | -2.92 Million | -5.23 Million | -163.16 Thousand | -151.91 Thousand | -77.24 Thousand | -43.51 Million |
| Cash at beginning of period | 490.64 Million | 656.57 Million | 844.83 Million | 844.31 Million | 122.1 Million | 75.98 Million |
| Cash at end of period | 239.67 Million | 490.64 Million | 656.57 Million | 844.83 Million | 844.31 Million | 122.1 Million |
| Capital Expenditure | -297.67 Million | -249.46 Million | -173.42 Million | -33.09 Million | -23.27 Million | -12.34 Million |
| Effect of forex changes on cash | 1.46 Million | 7.02 Million | -1.81 Million | -936.92 Thousand | 705.87 Thousand | 1.87 Million |
| Net cash flow / Change in cash | -250.96 Million | -165.93 Million | -188.26 Million | 519.14 Thousand | 722.21 Million | 46.12 Million |
| Free Cash Flow | -228.79 Million | -73.06 Million | -70.13 Million | 112.78 Million | 108.67 Million | 93.82 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 16 Million | 43.57 Million | 24.31 Million | 86.36 Million | 31.1 Million | 25.56 Million |
| Depreciation & Amortization | - | 28.64 Million | - | 48.34 Million | 48.34 Million | -23.51 Million |
| Deferred income taxes | - | - | - | 132.49 Thousand | - | 3.86 Million |
| Stock-based compensation | - | - | - | -4.35 Million | -4.35 Million | -5.09 Million |
| Change in working capital | - | 23.07 Million | - | -77.67 Million | -88.24 Million | 23.77 Million |
| Other non-cash items | -34.1 Million | -14.48 Million | 19.07 Million | 860.91 Thousand | -31.1 Million | -19.36 Million |
| Investing Cash Flow | -80.74 Million | -40.56 Million | -91.44 Million | -287.29 Million | -47.77 Million | -64.14 Million |
| Investments in PPE | -66.55 Million | -34.65 Million | -51.64 Million | -297.67 Million | -85.95 Million | -85.15 Million |
| Acquisitions | 92.71 Thousand | - | 55.71 Thousand | 16.8 Million | 25 Million | 29.3 Thousand |
| Investment purchases | -7.96 Million | - | - | -30.14 Million | 236.35 Million | -29.3 Thousand |
| Sales/Maturities of investments | -6.31 Million | 24.06 Million | 136.6 Thousand | 7.49 Million | -256.08 Million | 20.98 Million |
| Other Investing Activities | 92.71 Thousand | -5.9 Million | -40 Million | 32.77 Million | 13.17 Million | 29.3 Thousand |
| Financing Cash Flow | 2.22 Million | -30.19 Million | -96.35 Thousand | -34.01 Million | 8.08 Million | -26.61 Million |
| Debt repayment | -2.49 Million | -3.82 Million | - | -19 Million | -1 Million | -5 Million |
| Dividends payments | -105.32 Thousand | -33.71 Million | -96.35 Thousand | -36.06 Million | -36.06 Million | -36.11 Million |
| Common Stock Repurchased | - | - | - | - | -9 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -163.4 Thousand | 3.51 Million | -96.35 Thousand | 21.56 Million | 7.2 Million | 14.49 Million |
| Accounts receivables | - | 22.49 Million | - | -45.73 Million | -45.73 Million | -24.2 Million |
| Accounts payables | - | - | - | 7.51 Million | - | 5.81 Million |
| Inventory | - | 74.16 Thousand | - | -39.58 Million | -39.58 Million | 47.97 Million |
| Other working capital | - | 515 Thousand | - | -2.92 Million | -2.92 Million | -5.81 Million |
| Cash at beginning of period | 203.07 Million | 191.77 Million | 239.67 Million | 490.64 Million | 236.25 Million | 321.31 Million |
| Cash at end of period | 105.6 Million | 203.07 Million | 191.77 Million | 239.67 Million | 239.67 Million | 236.25 Million |
| Capital Expenditure | -66.55 Million | -34.65 Million | -51.64 Million | -297.67 Million | -85.95 Million | -85.15 Million |
| Effect of forex changes on cash | -551.17 Thousand | 1.23 Million | 255.12 Thousand | 1.46 Million | -598.44 Thousand | 466.8 Thousand |
| Net cash flow / Change in cash | -97.46 Million | 11.3 Million | -47.9 Million | -250.96 Million | 3.42 Million | -85.06 Million |
| Free Cash Flow | -84.65 Million | 46.16 Million | -8.25 Million | -228.79 Million | -42.24 Million | -79.92 Million |
RELAXO
002922
TRI
HLUN-A
KRIDHANINF
SDXOF